Compare Stocks

Date Range: 

 Gritstone OncologyJounce TherapeuticsOptheaAptose BiosciencesLineage Cell Therapeutics
SymbolNASDAQ:GRTSNASDAQ:JNCENASDAQ:OPTNASDAQ:APTONYSEAMERICAN:LCTX
Price Information
Current Price$8.13$7.92$8.64$4.81$2.75
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.61.61.51.41.6
Analysis Score3.23.33.43.53.5
Community Score2.72.74.32.73.1
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.00.80.8
Earnings & Valuation Score0.60.60.00.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$22.33$15.50$36.00$11.63$5.60
% Upside from Price Target174.70% upside95.71% upside316.67% upside141.68% upside103.64% upside
Trade Information
Market Cap$399.98 million$405.57 million$375.47 million$431.26 million$457.44 million
Beta1.21.34N/A1.622.11
Average Volume2,638,922486,03411,0303,408,2221,683,758
Sales & Book Value
Annual Revenue$4.36 million$147.87 millionN/AN/A$3.52 million
Price / Sales91.742.74N/AN/A126.28
CashflowN/A$1.93 per shareN/AN/A$0.21 per share
Price / CashN/A4.11N/AN/A13.32
Book Value$3.75 per share$5.25 per shareN/A$1.23 per share$0.74 per share
Price / Book2.171.51N/AN/A3.72
Profitability
Net Income$-94,430,000.00$56.82 millionN/A$-26,280,000.00$-11,710,000.00
EPS($2.81)$1.66N/A($0.52)$0.14
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,962.52%N/AN/AN/A-1,001.59%
Return on Equity (ROE)-101.31%-72.91%N/A-49.53%-26.07%
Return on Assets (ROA)-68.78%-59.68%N/A-46.65%-22.91%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.29%N/AN/AN/AN/A
Current Ratio3.35%6.60%N/A24.60%5.13%
Quick Ratio3.35%6.60%N/A24.60%5.13%
Ownership Information
Institutional Ownership Percentage58.98%60.48%N/A52.22%35.72%
Insider Ownership Percentage38.00%43.96%N/A6.30%29.00%
Miscellaneous
Employees169128N/A3149
Shares Outstanding49.20 million51.21 million43.46 million88.92 million161.64 million
Next Earnings Date8/4/2021 (Estimated)8/6/2021 (Estimated)N/A8/3/2021 (Estimated)5/13/2021 (Confirmed)
OptionableNot OptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Lineage Cell Therapeutics (LCTX) Scheduled to Post Quarterly Earnings on ThursdayLineage Cell Therapeutics (LCTX) Scheduled to Post Quarterly Earnings on Thursday
americanbankingnews.com - May 6 at 3:36 AM
Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of DirectorsLineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
finance.yahoo.com - May 5 at 11:02 AM
Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
finance.yahoo.com - May 4 at 8:27 AM
Lineage Cells Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved VisionLineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved Vision
finance.yahoo.com - May 3 at 4:21 PM
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic AtrophyOpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
finance.yahoo.com - May 3 at 9:18 AM
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Given Average Recommendation of "Buy" by BrokeragesLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 30 at 12:54 PM
Lineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseLineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
finance.yahoo.com - April 29 at 8:15 PM
Good News For Lineage Cell Therapeutics, Inc. (NYSE:LCTX): Stock Could Go Up 169.23% MoreGood News For Lineage Cell Therapeutics, Inc. (NYSE:LCTX): Stock Could Go Up 169.23% More
stocksregister.com - April 27 at 8:38 AM
Why Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Stock Should Not Be Discarded By Investors In 2021Why Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Stock Should Not Be Discarded By Investors In 2021
marketingsentinel.com - April 26 at 1:06 PM
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
finance.yahoo.com - April 26 at 8:02 AM
What Type Of Shareholders Own The Most Number of Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) Shares?What Type Of Shareholders Own The Most Number of Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) Shares?
nasdaq.com - April 24 at 9:30 AM
Lineage Announces Appointment of Dr. Dipti Amin to Its Board of DirectorsLineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors
finance.yahoo.com - April 22 at 8:41 AM
Why Lineage Cell Therapeutics Stock Popped TodayWhy Lineage Cell Therapeutics Stock Popped Today
finance.yahoo.com - April 20 at 6:27 PM
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC PlatformLineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform
finance.yahoo.com - April 20 at 8:17 AM
OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MDOpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD
finance.yahoo.com - April 12 at 8:51 AM
Thinking about buying stock in Arcadia Biosciences, Ocugen, Broadwind, Surface Oncology, or Lineage Cell Therapeutics?Thinking about buying stock in Arcadia Biosciences, Ocugen, Broadwind, Surface Oncology, or Lineage Cell Therapeutics?
cnweekly.com - April 1 at 12:42 PM
Lineages Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate UseLineage's Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate Use
finance.yahoo.com - March 29 at 2:33 PM
Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate UseLineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use
finance.yahoo.com - March 29 at 9:32 AM
Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic AtrophyLineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
finance.yahoo.com - March 23 at 8:35 AM
Lineage Set to Turn Cell Therapy on its Head with 3 Clinical Programs in 2021Lineage Set to Turn Cell Therapy on its Head with 3 Clinical Programs in 2021
benzinga.com - March 19 at 1:29 PM
Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021
finance.yahoo.com - March 17 at 8:37 AM
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Lineage Cell Therapeutics (LCTX)Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Lineage Cell Therapeutics (LCTX)
smarteranalyst.com - March 16 at 7:18 PM
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2020 Earnings Call TranscriptLineage Cell Therapeutics, Inc. (LCTX) Q4 2020 Earnings Call Transcript
fool.com - March 12 at 3:16 AM
Lineage Cell: Q4 Earnings SnapshotLineage Cell: Q4 Earnings Snapshot
finance.yahoo.com - March 11 at 6:31 PM
Lineage Cell: Q4 Earnings Snapshot | Raleigh News & ObserverLineage Cell: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - March 11 at 6:31 PM
DateCompanyBrokerageAction
1/21/2021Gritstone OncologyBTIG ResearchBoost Price Target
1/20/2021Gritstone OncologyHC WainwrightBoost Price Target
1/20/2021Gritstone OncologyRobert W. BairdDowngrade
1/15/2020Gritstone OncologyCowenReiterated Rating
3/27/2019Gritstone OncologyBerenberg BankInitiated Coverage
3/14/2019Gritstone OncologyRaymond JamesInitiated Coverage
10/23/2018Gritstone OncologyBarclaysInitiated Coverage
10/23/2018Gritstone OncologyThe Goldman Sachs GroupInitiated Coverage
3/22/2021Jounce TherapeuticsPiper SandlerInitiated Coverage
11/10/2020Jounce TherapeuticsRoth CapitalLower Price Target
8/21/2020Jounce TherapeuticsJPMorgan Chase & Co.Reiterated Rating
11/18/2020OptheaCIBCReiterated Rating
11/17/2020OptheaSmith Barney CitigroupInitiated Coverage
11/17/2020OptheaCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
11/11/2020OptheaSVB LeerinkInitiated Coverage
11/11/2020OptheaOppenheimerInitiated Coverage
11/11/2020OptheaTruistInitiated Coverage
2/22/2021Aptose BiosciencesJonestradingInitiated Coverage
10/20/2020Aptose BiosciencesCanaccord GenuityReiterated Rating
10/19/2020Aptose BiosciencesCantor FitzgeraldInitiated Coverage
9/22/2020Aptose BiosciencesAlliance Global PartnersInitiated Coverage
6/12/2020Aptose BiosciencesMaxim GroupInitiated Coverage
3/1/2019Aptose BiosciencesRoyal Bank of CanadaInitiated Coverage
4/7/2021Lineage Cell TherapeuticsChardan CapitalReiterated Rating
10/12/2020Lineage Cell TherapeuticsDawson JamesReiterated Rating
9/17/2020Lineage Cell TherapeuticsNoble FinancialInitiated Coverage
(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.